Back
67
Day Range
$73.81
$75.95
52-Week Range
$56.71
$99.50
Volume
237,307
50D / 200D Avg
$78.57
/
$80.76
Prev Close
$74.67
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (626 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 21.2 | 0.4 |
| P/B | 3.1 | 2.9 |
| ROE % | 16.2 | 3.8 |
| Net Margin % | 8.9 | 3.9 |
| Rev Growth 5Y % | 42.2 | 10.0 |
| D/E | 0.6 | 0.2 |
Key Takeaways
Revenue grew 42.18% annually over 5 years — strong growth
ROE of 16.16% — decent returns on equity
Generating 171.39M in free cash flow
Cash machine — converts 218.79% of earnings into free cash flow
Capital efficient — spends only 1.57% of revenue on capex
Growth
Revenue Growth (5Y)
42.18%
Revenue (1Y)43.78%
Earnings (1Y)N/A
FCF Growth (3Y)30.62%
Quality
Return on Equity
16.16%
ROIC7.04%
Net Margin8.87%
Op. Margin9.20%
Safety
Debt / Equity
0.60
Current Ratio2.71
Interest Coverage4.05
Valuation
P/E Ratio
21.19
P/B Ratio3.07
EV/EBITDA20.92
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 43.78% | Revenue Growth (3Y) | 34.71% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | 104.24% |
| Revenue Growth (5Y) | 42.18% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 883.37M | Net Income (TTM) | 78.34M |
| ROE | 16.16% | ROA | 5.44% |
| Gross Margin | 51.01% | Operating Margin | 9.20% |
| Net Margin | 8.87% | Free Cash Flow (TTM) | 171.39M |
| ROIC | 7.04% | FCF Growth (3Y) | 30.62% |
| Safety | |||
| Debt / Equity | 0.60 | Current Ratio | 2.71 |
| Interest Coverage | 4.05 | Dividend Yield | 0.00% |
| Valuation | |||
| P/E Ratio | 21.19 | P/B Ratio | 3.07 |
| P/S Ratio | 1.88 | PEG Ratio | -0.05 |
| EV/EBITDA | 20.92 | Dividend Yield | 0.00% |
| Market Cap | 1.66B | Enterprise Value | 1.70B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 883.37M | 614.38M | 486.82M | 316.39M | 216.14M |
| Net Income | 78.34M | -18.52M | 18.78M | -47.90M | -42.60M |
| EPS (Diluted) | 3.32 | -1.04 | 0.94 | -3.05 | -3.40 |
| Gross Profit | 450.64M | 364.17M | 305.30M | 177.60M | 115.53M |
| Operating Income | 81.23M | 584,000.0 | 46.97M | -35.28M | -39.79M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1.44B | 1.28B | 904.42M | 760.09M | 771.60M |
| Total Liabilities | 899.65M | 855.17M | 446.82M | 421.55M | 412.86M |
| Shareholders' Equity | 540.72M | 428.53M | 457.60M | 338.54M | 358.74M |
| Total Debt | 325.20M | 624.09M | 285.67M | 286.52M | 287.37M |
| Cash & Equivalents | 285.59M | 144.86M | 221.12M | 48.23M | 100.30M |
| Current Assets | 753.12M | 527.68M | 519.82M | 344.26M | 321.78M |
| Current Liabilities | 278.11M | 193.68M | 145.48M | 99.44M | 87.54M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#123 of 1024
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026